Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Macular Edema, Diabetic Clear all
Active, not recruiting Phase 4 Interventional

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Aflibercept 8mg
Drug
Lead sponsor
Edward Wood, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Austin, Texas • Bellaire, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

NCT02050828
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
AKB-9778, ranibizumab, Placebo, Sham
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Pheonix, Arizona • Tucson, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

NCT00168337
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Jul 23, 2026, 3:09 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839
View directory record Official record
Conditions
Macular Edema
Interventions
BI 1815368, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Arcadia, California • Huntington Beach, California • Modesto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional

Phase 4 IOP Signals Associated With ILUVIEN®

NCT02424019
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
ILUVIEN 0.19 MG
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema

NCT00069056
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Treatment
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 3:09 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)

NCT05802329
View directory record Official record
Conditions
Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Interventions
OCU200
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Deerfield Beach, Florida • Erie, Pennsylvania • Bellaire, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

NCT03238963
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 1467335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

NCT00464685
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham injection, Laser Photocoagulation
Drug · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 23, 2026, 3:09 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

NCT06116916
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
KHK4951, Aflibercept Injection
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Mesa, Arizona • Tucson, Arizona • Arcadia, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jul 23, 2026, 3:09 PM EDT
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 23, 2026, 3:09 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluation of Tonabersat for DME

NCT05727891
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Tonabersat, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Huntington Beach, California • Loma Linda, California • Oakland, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional Results available

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 23, 2026, 3:09 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

NCT04362241
View directory record Official record
Conditions
Retinopathy, Diabetic
Interventions
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Drug
Lead sponsor
Ophthalmic Consultants of the Capital Region
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jul 23, 2026, 3:09 PM EDT
Not listed No phase listed Observational

Iluvien Registry Safety Study

NCT01998412
View directory record Official record
Conditions
Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies
Interventions
Not listed
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 23, 2026, 3:09 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

NCT06847854
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RO7497372
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

NCT06771271
View directory record Official record
Conditions
Diabetic Macular Edema, Uveitic Macular Edema
Interventions
RO7200220, Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Beverly Hills, California • Oxnard, California • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 3 Interventional Results available

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

NCT00090519
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
36
States / cities
Artesia, California • Palm Springs, California • Poway, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional

Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

NCT00758628
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Bromefenac, Blink
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
140 East 80th Street New York, NY 10075, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 1 Interventional

Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study

NCT00846092
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Warp 10 LED Device, Near-infrared light (NIR)
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Jul 23, 2026, 3:09 PM EDT
Completed Phase 4 Interventional Results available

Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)

NCT01613716
View directory record Official record
Conditions
Diabetic Macular Edema, Epiretinal Membrane
Interventions
Ozurdex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Jul 23, 2026, 3:09 PM EDT
Completed No phase listed Observational

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

NCT06769412
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 23, 2026, 3:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

NCT01918371
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Anti-VEGF
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 23, 2026, 3:09 PM EDT